» Articles » PMID: 9108381

Extensive Amplification and Self-renewal of Human Primitive Hematopoietic Stem Cells from Cord Blood

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1997 Apr 15
PMID 9108381
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

The use of umbilical cord blood as a source of marrow repopulating cells for the treatment of pediatric malignancies has been established. Given the general availability, the ease of procurement, and progenitor content, cord blood is an attractive alternative to bone marrow or growth factor mobilized peripheral blood cells as a source of transplantable hematopoietic tissue. However, there is a major potential limitation to the widespread use of cord blood as a source of hematopoietic stem cells for marrow replacement and gene therapy. There may be enough hematopoietic stem cells to reconstitute children, but the ability to engraft an adult might require ex vivo manipulations. We describe an in vitro system in which the growth of cord blood CD34+ cells is sustained and greatly expanded for more than 6 months by the simple combination of two hematopoietic growth factors. Progenitors and cells belonging to all hematopoietic lineages are continuously and increasingly generated (the number of colony-forming unit-granulocyte-macrophage [CFU-GM] present at the end of 6 months of culture are well over 2,000,000-fold the CFU-GM present at the beginning of the culture). Very primitive hematopoietic progenitors, including long-term culture-initiating cells (LTC-ICs) and blast cell colony-forming units, are also greatly expanded (after 20 weeks of liquid culture, LTC-IC number is over 200,000-fold the initial number). The extremely prolonged maintenance and the massive expansion of these progenitors, which share many similarities with murine long-term repopulating cells, suggest that extensive renewal and little differentiation take place. This system might prove useful in diverse clinical settings involving treatment of grown-up children and adults with transplantation of normal or genetically manipulated hematopoietic stem cells.

Citing Articles

Umbilical cord blood stem cells as third-party adjuvant infusions in human leukocyte antigen antibody-positive patients undergoing haploidentical hematopoietic stem cell transplantation.

Wang Y, Zhao Y, Fang X, Yuan D, Ding M, Lu K Front Immunol. 2024; 15:1459699.

PMID: 39399498 PMC: 11466763. DOI: 10.3389/fimmu.2024.1459699.


Umbilical cord blood derived cell expansion: a potential neuroprotective therapy.

Penny T, Jenkin G, Miller S, McDonald C Stem Cell Res Ther. 2024; 15(1):234.

PMID: 39075614 PMC: 11287950. DOI: 10.1186/s13287-024-03830-0.


Advances in ex vivo expansion of hematopoietic stem and progenitor cells for clinical applications.

Branco A, Rayabaram J, Miranda C, Fernandes-Platzgummer A, Fernandes T, Sajja S Front Bioeng Biotechnol. 2024; 12:1380950.

PMID: 38846805 PMC: 11153805. DOI: 10.3389/fbioe.2024.1380950.


In vitro expansion of fetal liver hematopoietic stem cells.

Bhardwaj R, Kumar L, Chhabra D, Mehra N, Sharma A, Mohanty S Sci Rep. 2021; 11(1):11879.

PMID: 34088934 PMC: 8178329. DOI: 10.1038/s41598-021-91272-6.


Cord blood transplantation for bone marrow failure syndromes: state of art.

Pagliuca S, Ruggeri A, Peffault de Latour R Stem Cell Investig. 2020; 6:39.

PMID: 32039261 PMC: 6987328. DOI: 10.21037/sci.2019.10.04.